Back to Search
Start Over
Susceptibility of Human T Cell Leukemia Virus Type 1 to Reverse-Transcriptase Inhibitors: Evidence for Resistance to Lamivudine.
- Source :
-
Journal of Infectious Diseases . 8/15/2001, Vol. 184 Issue 4, p507. 4p. - Publication Year :
- 2001
-
Abstract
- Nucleoside reverse-transcriptase (RT) inhibitors (NRTIs), including lamivudine (3TC) and zidovudine (Zdv), are being evaluated for the treatment of human T cell lymphotropic virus type 1 (HTLV-1)-associated disease. However, information on the susceptibility of HTLV-1 to these drugs is limited. The activity of 5 NRTIs on HTLV-1 RT was evaluated. IC[sub 50] values for Zdv, zalcitabine (ddC), didanosine (ddI), 3TC, and stavudine (d4T) were determined, using an enzymatic assay, for 5 HTLV-1 isolates and for reference wild-type and NRTI-resistant human immunodeficiency virus type 1 (HIV-1). Both HTLV-1 and wild-type HIV-1 were equally susceptible to Zdv, ddC, ddI, and d4T. In contrast, high-level resistance to 3TC was found in all HTLV-1 isolates. The findings support the clinical use of Zdv, ddC, ddI, and d4T but not of 3TC for the antiretroviral treatment of HTLV-1-associated disease. [ABSTRACT FROM AUTHOR]
- Subjects :
- *HTLV-I
*REVERSE transcriptase
Subjects
Details
- Language :
- English
- ISSN :
- 00221899
- Volume :
- 184
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Journal of Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 5502529